Predictive factors of late biochemical recurrence after radical prostatectomy
|
|
- Luke Frank Pearson
- 6 years ago
- Views:
Transcription
1 JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) doi: /jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original Article Predictive factors of late biochemical recurrence after radical prostatectomy Takahito Negishi 1, *, Kentarou Kuroiwa 2, Yoshifumi Hori 2, Toshihisa Tomoda 3, Hiroshi Uchino 4, Noriaki Tokuda 4, Nobuki Furubayashi 1, Kei Nagase 1, Hidenori Iwai 1, and Motonobu Nakamura 1 1 Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, 2 Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, 3 Department of Urology, Oita Prefectural Hospital, Oita, and 4 Department of Urology, Saga-Ken Medical Center Koseikan, Saga, Japan *For reprints and all correspondence: Takahito Negishi, National Hospital Organization Kyushu Cancer Center, 3-3-1, Notame, Minami-ku Fukuoka-shi, Fukuoka , Japan. negishi.t@nk-cc.go.jp Received 31 August 2016; Editorial Decision 21 November 2016; Accepted 23 November 2016 Abstract Objective: To assess the characteristics of biochemical recurrence in the late period (>5 years after radical prostatectomy) and the differences in the predictors of biochemical recurrence in different periods, we conducted a multicenter retrospective study. Methods: We reviewed 478 men who underwent radical prostatectomy for clinically localized prostate cancer. All of the patients were followed up for at least 5 years. The cohort was then divided into three groups; no recurrence group, recurrence <5 years after surgery group and recurrence 5 years after surgery group. The background characteristics of each group were compared using the χ 2 test. A Cox multivariate regression analysis was performed to determine the predictors of biochemical recurrence in each period. Results: Biochemical recurrence occurred in 135 men. In 113 (84%) of the patients, biochemical recurrence occurred at <5 years after surgery; in 22 (16%), it occurred at 5 years after surgery. The proportion of men with a low preoperative prostate-specific antigen level was significantly larger in the latter group (P = ). A preoperative prostate-specific antigen level and a positive surgical margin were significant predictors of biochemical recurrence at <5 years after surgery (hazard ratio: 1.03 and 3.20). A positive surgical margin was also a significant predictor of biochemical recurrence at 5 years after surgery (hazard ratio: 3.03); however, a high preoperative prostate-specific antigen level was not. Conclusions: Biochemical recurrence occurred at 5 years after surgery in 16% of the patients. A positive surgical margin predicted biochemical recurrence in both the early and late periods. Key words: radical prostatectomy, biochemical recurrence, predictive factor, prostate cancer, positive surgical margin Introduction In 2013, 1.4 million men were affected with prostate cancer, which is the most common of male-specific cancer, and 290,000 men died from prostate cancer, which was the sixth leading cause of cancer death in males, in the world (1). At the same time, men with localized prostate cancer who receive appropriate treatment can expect long-term survival. Radical prostatectomy (RP), which has been performed safely since Reiner et al. reported an anatomical approach to the surgical management of the dorsal vein, remains one of the most efficacious treatment modalities (2 4). After The Author Published by Oxford University Press. All rights reserved. For permissions, please journals.permissions@oup.com 233
2 234 Late recurrence after prostatectomy surgery, surveillance is conducted by periodic prostate-specific antigen (PSA) monitoring. PSA elevation, which is termed biochemical recurrence (BCR), occurs in 15 33% of patients (5 7). Because BCR has been reported to lead to distant metastasis and cancer death, it is necessary for men with BCR to undergo salvage therapy or to be followed up closely (5,8). While BCR usually occurs in early period (within 5 years after RP), some cases occur in the late period (>5 years after RP)(7,9). Although it has been reported that the backgrounds of patients with BCR differ according to the period after surgery in which BCR occurs (7,10), it remains controversial whether the prognosis differs according to the time of recurrence (5,6).With regard to salvage therapy for BCR,most patients in past studies about salvage therapy suffered from recurrence in the early period after BCR (11 13). It is therefore unknown whether salvage therapy for BCR in the late period is necessary or when treatment should be administered to such patients. In spite of the lack of knowledge about BCR at 5 years after surgery, because of the possibility of distant metastasis, patients should be followed up for a long period of time and there is no evidence as to when surveillance can be safely ended; however, the probability of BCR advancing to life-threatening disease might differ according to the period of recurrence (14). There are some reports about predictors of BCR at <5 years after surgery (15,16). In contrast, there have been few studies on predictors of BCR at 5 years after surgery (14). At present, RP has been widely performed for a long time, thus there are many long-term survivors undergoing RP and it is important to recognize the predictive factors of BCR, not only in the early period after surgery but also in the late period. We conducted a multicenter retrospective study to assess the different predictors of BCR in the different periods. Patients and methods We reviewed 478 men who underwent open retropubic RP for clinically localized prostate cancer without neoadjuvant hormonal therapy at four hospitals from 1999 to All of the patients were followed up for at least 5 years after RP. The four hospitals are all hub medical institutions for cancer treatment in their respective prefectures in Japan. The present study was approved by the institutional review board of the National Hospital Organization Kyushu Cancer Center. After RP, PSA measurement was performed every few months and radiographic imaging was not routinely conducted. Because this was a retrospective analysis, the follow-up protocols were not predetermined and the schedules of PSA measurement were determined by each physician. Postoperative therapy, including adjuvant or salvage treatment, was administered to 114 men during the follow-up period. In all cases, this involved radiation therapy to the prostate bed or hormonal therapy. The treatment modality was determined by the individual physicians. BCR was defined as a single PSA level of 0.2 ng/ml or the initiation of postoperative therapy for a PSA level of <0.2 ng/ml, because until 2010, the Japanese classification of prostate cancer defined BCR after RP as three consecutive PSA increases (17). Thus, some of the patients who received postoperative therapy had a PSA level of <0.2 ng/ml. The date of BCR was defined as the day when the PSA level increased to 0.2 ng/ml for the first time after RP or when salvage treatment was initiated while the PSA level was <0.2 ng/ml. If the PSA level had never been reduced to <0.2 ng/ml after RP, then the date of the surgery was defined as the date of BCR. Metastases were diagnosed based on the review of computed tomography, magnetic resonance imaging or bone scan images. The physicians performed diagnostic imaging when the PSA level increased. The Kaplan Meier method was used to estimate the BCR-free survival rate at 5 and 10 years after RP. The patients in whom BCR occurred during the follow-up period were divided into three groups. The first group contained men who did not undergo BCR; the second group contained men in whom BCR occurred at <5 years after RP; the third group contained men in whom BCR occurred at 5 years after RP. The background characteristics of each group were compared using the χ 2 test. The background characteristics of men who received postoperative therapy were compared according to their PSA level at the initiation of the additional treatment, with the χ 2 test used to compare categorical variables and Student s t-test used to compare continuous variables. A Cox multivariate regression analysis was performed to test the association of clinical or pathological parameters with BCR at <5 years and 5 years after RP. The covariates included the preoperative PSA level, the margin status, the pathological T stage and the Gleason score. Hazards ratios and the corresponding 95% confidence intervals were determined for each covariate. Two-sided P values of <0.05 were considered to indicate statistically significant differences. All of the analyses were performed using the JMP Pro software package (version 9.0.2, SAS Institute, Inc., Cary, NC, USA). Results Table 1 shows the characteristics of the 478 patients. The median follow-up period was 7.5 years (range: years). A total of 135 patients had BCR. In 113 (84%) of the patients, BCR occurred at <5 years after RP; in 22 (16%) patients BCR occurred at 5 years after RP. The 5-year and 10-year recurrencefree survival rates were 76.3 and 67.9%, respectively (Fig. 1). The preoperative PSA level, margin status, pathological features and incidence of distant metastasis in each group are shown in Table 1. The proportion of patients in whom the preoperative PSA level was >10 ng/ml and seminal vesicle invasion was significantly larger in patients with BCR at <5 yearsafterrpthaninpatientswithbcrat 5 years after RP. There were no significant differences between the two groups in the margin status or pathological features, including extracapsular extension (EPE) and Gleason score. Postoperative therapy was administered to a significantly higher proportion of the patients with BCR at <5 years after RP. With respect to the prognosis, there was no difference between the two groups in the incidence of metastasis and no patients died of prostate cancer in this cohort. Postoperative therapy was administered to 114 men. Table 2 shows their characteristics. Thirty-eight (33%) men received postoperative therapy before the PSA level increased to 0.2 ng/ml. Their preoperative PSA and pathological features were not significantly different from those of the men who underwent postoperative therapy with a PSA level of 0.2 ng/ml (Table 2A). On the other hand, they were less favorable than those of men in whom BCR did not occur (Table 2B). The multivariate analysis revealed that a preoperative PSA level and a positive surgical margin were significant predictors of BCR at <5 years after RP (HR: 1.03 and 3.20) (Table 3A). On the other hand, among 365 patients in whom BCR did not occur for 5 years after RP, a positive surgical margin was the only significant predictor of BCR at 5 years after RP (HR: 3.03) (Table 3B). Discussion Fifteen to thirty-three of patients who undergo RP for clinically localized prostate cancer are reported to experience BCR (5 7). Although 77 94% of BCR occurs within the early (<5 years after RP), it can
3 Jpn J Clin Oncol, 2017, Vol. 47, No Table 1. A comparison of the characteristics of the patients with PSA recurrence 5 years and >5 years after surgery Characteristics Total (n = 478) BCR 5 years (n = 113) BCR >5 years (n = 22) P Patients (%) Patients (%) Patients (%) Age (17) 18 (16) 6 (27) (59) 64 (57) 12 (55) (24) 31 (27) 4 (18) Preoperative PSA (ng/ml) (66) 50 (44) 18 (82) >10, (25) 47 (42) 2 (9) >20 43 (9) 16 (14) 2 (9) Surgical margin Positive 119 (25) 57 (50) 13 (59) Negative 355 (74) 56 (50) 8 (36) Unknown 4 (1) 0 1 (5) Pathological stage EPE (64) 58 (51) 11 (50) (35) 54 (48) 10 (45) Unknown 6 (1) 1 (1) 1 (5) SVI (94) 101 (89) 21 (95) (5) 11 (10) 0 Unknown 6 (1) 1 (1) 1 (5) pn pn0 461 (96) 105 (93) 22 (100) pn1 9 (2) 8 (7) 0 Unknown 8 (2) 0 0 Pathological Gleason score (24) 24 (21) 4 (19) (53) 50 (44) 14 (67) (23) 39 (35) 3 (14) Unknown No. of salvage therapy 114 (24) 101 (89) 13 (59) No. of metastasis 4 (1) 3 (3) 1 (5) BCR, biochemical recurrence; PSA, prostate-specific antigen; EPE, extracapsular extension; SVI, seminal vesicle invasion. Figure 1. BCR-free survival curve. BCR, biochemical recurrence. also occur in the late period ( 5 years after RP) (7,9). Similarly to previous studies, BCR occurred in 135 of the 478 patients in the present cohort; in 113 (84%) cases, BCR occurred at <5 years after RP, while in 22 (16%) cases, BCR occurred at 5 years after RP. The latest case of BCR occurred 11.4 years after RP. The accumulated evidence regarding the prognosis of patients with BCR at 5 years after RP is insufficient. Loeb and Caire reported that cases in which BCR occurs at 5 years after RP are less likely to progress to metastasis or cancer death than cases in which BCR occurs at <5 years after RP (7,10). On the other hand, Boorijian reported that the time from RP to BCR was not significantly associated with the risk of systemic progression or cancer-specific mortality (5). However, this issue remains controversial. The background characteristics of patients with BCR, including the preoperative PSA, pathological stage and margin status, differ according to the timing of BCR (7,10); thus, the prognosis after BCR may differ according to the periods from RP to BCR. At any rate, BCR that occurs at 5 years after RP has the potential to progress to metastasis or cancer death, so it is necessary for patients who undergo RP to be followed up for a long period of time, and for salvage therapy to be administered in some cases. Some studies have reported that the preoperative PSA, a positive surgical margin, pathological stage and other factors are predictors of BCR (18 20). In line with previous reports, we found that the preoperative PSA and a positive surgical margin were predictors of BCR at <5 years after RP. When we investigated the patients in whom BCR occurred at 5 years after RP, a positive surgical margin remained a predictor of BCR but the preoperative PSA did not. Ahove conducted similar research and concluded that the pathological stage and Gleason score were predictors of BCR at 5 years
4 236 Late recurrence after prostatectomy Table 2. A comparison of the characteristics of patients undergoing postoperative therapy with PSA levels <0.2 and 0.2 ng/ml (A) and the characteristics of patients without BCR with who underwent postoperative therapy with a PSA level of <0.2 ng/ml (B) (A) Characteristics Total (n = 114) Initiation of postoperative therapy with PSA < 0.2 (n = 38) Initiation of postoperative therapy with PSA 0.2 (n = 76) P Median PSA at initiation of postoperative 0.31 ( ) ( ) 0.6 ( ) < therapy, ng/ml (range) Median period from surgery to postoperative 472 (3 4320) 203 (3 3565) 580 ( ) therapy, day (range) Median preoperative PSA, ng/ml (range) ( ) 10.4 ( ) ( ) Modality of treatment, no. (%) Hormonal therapy 78 (68) 19 (50) 59 (78) Radiation therapy to prostate bed 36 (32) 19 (50) 17 (22) Surgical margin, no. (%) Positive 56 (49) 22 (58) 34 (45) Negative 58 (51) 16 (42) 42 (55) Pathological stage, no. (%) EPE 0 49 (43) 13 (34) 36 (47) (56) 24 (63) 40 (53) Unknown 1 (1) 1 (3) SVI (89) 31 (81) 71 (93) (10) 6 (16) 5 (7) Unknown 1 (1) 1 (3) pn pn0 105 (92) 34 (90) 71 (93) pn1 7 (6) 2 (5) 5 (7) Unknown 2 (2) 2 (5) Pathological Gleason score, no. (%) 6 24 (21) 10 (26) 14 (18) (45) 17 (45) 34 (45) (34) 11 (29) 28 (37) (B) Characteristics Survival without BCR (n = 343) Initiation of postoperative therapy with PSA < 0.2 (n = 38) P Median PSA at initiation of postoperative therapy, ng/ml (range) ( ) Median period from surgery to postoperative therapy, day (range) 203 (3 3565) Median preoperative PSA, ng/ml (range) 7.37 ( ) 10.4 ( ) <0.001 Modality of treatment (%) Hormonal therapy 19 (50) Radiation therapy to prostate bed 19 (50) Surgical margin (%) Positive 55 (16) 22 (58) <0.001 Negative 285 (83) 16 (42) Unknown 3 (1) Pathological stage (%) EPE (70) 13 (34) < (29) 24 (63) Unknown 4 (1) 1 (3) SVI (95) 31 (81) (4) 6 (16) Unknown 4 (1) 1 (3) pn pn0 336 (98) 34 (90) pn1 1 2 (5) Unknown 6 (2) 2 (5) Pathological Gleason score (%) 6 89 (26) 10 (26) (55) 17 (45) (19) 11 (29) Unknown 1
5 Jpn J Clin Oncol, 2017, Vol. 47, No Table 3. Univariate and multivariate analyses of various factors affecting recurrence at <5 years (A) and 5 years after surgery (B) (A) n Univariate analysis P Multivariate analysis P Preoperative PSA Elevation of PSA by 1 ng/ml ( ) < ( ) < Surgical margin Negative (reference) 1 (reference) Positive ( ) < ( ) < Unknown 4 Extracapsular extension Negative (reference) 1 (reference) Positive ( ) < ( ) Unknown 6 Seminal vesicle invasion Negative (reference) 1 (reference) Positive ( ) ( ) Unknown 6 Pathological Gleason score (reference) 1 (reference) ( ) ( ) ( ) ( ) Unknown 2 (B) n Univariate analysis P Multivariate analysis P Preoperative PSA Elevation of PSA by 1 ng/ml ( ) ( ) Surgical margin Negative (reference) 1 (reference) Positive ( ) ( ) Unknown 4 Extracapsular extension Negative (reference) 1 (reference) Positive ( ) ( ) Unknown 5 Seminal vesicle invasion Negative (reference) 1 (reference) Positive Unknown 5 Pathological Gleason score (reference) 1 (reference) ( ) ( ) ( ) ( ) Unknown 2 HR, hazard ratio; CI, confidence interval. after RP (14). This finding was completely different from our results. Because there are only a few reports about the predictors of late BCR, it is difficult to suggest a reason for this difference. On one hand, the Kaplan Meier curves in their study showed that the patients with a high Gleason score or a high pathological stage (such as pt3b) experienced BCR at 5 years after RP. On the other hand, in our cohort, BCR in such patients usually occurred at <5 years after RP and there were only a few cases of BCR at 5 years after RP. Similarly, a report about the prognosis of Japanese patients after RP noted that among patients with a high Gleason score or a high pathological stage, BCR usually occurred at <5 years after RP (20). Although this discrepancy may be due to racial differences, the accumulation of further evidence is necessary to discuss this problem. High preoperative PSA and a positive surgical margin have been reported to predict BCR in the early period (18,20). In our study, the preoperative PSA level was a predictor of BCR in the early period, while patients with a positive surgical margin continued to develop BCR for a long period of time. It has been demonstrated that in patients with a positive surgical margin, the tumor grade at the site of the positive margin has prognostic value and that the Gleason score of the RP specimen is associated with PSA velocity (21,22). Considering these reports, it is hypothesized that among the cases with a positive surgical margin, the cases with a high tumor grade at the site of the positive margin undergo BCR in the early period after RP because of their high PSA velocity, while those with a low tumor grade at the site of the positive margin undergo BCR in the late period because of
6 238 Late recurrence after prostatectomy their low PSA velocity. Although, further studies on the relationship of the tumor grade at the margin site and the period from RP to BCR are required, it is necessary to follow-up cases in which there is a positive surgical margin for a long time after RP. The present study is associated with some limitations. First, some patients received postoperative therapy when their PSA was <0.2 ng/ml. This is partly because, until 2010, the Japanese classification of prostate cancer defined BCR after RP as three consecutive increases in the PSA level regardless of the absolute value. Thus, these patients received early postoperative therapy; however, their preoperative PSA level and pathological features were as unfavorable as those of the men whose PSA levels increased to 0.2 ng/ml after RP. Moreover, their preoperative PSA level and the rates of patients with a positive surgical margin, EPE, SVI and pn were significantly higher than those of the men in whom BCR did not occur. Thus, early BCR was expected to occur in these patients and the effects of the early postoperative therapy on the results are thought to be acceptable. Second, we did not discuss overall survival because of the short follow-up period and the absence of cancer-related mortality. Although the examination of the prognosis was insufficient, the elevation of the PSA level after RP has been reported to precede clinical recurrence or distant metastasis. It is therefore reasonable to set BCR as an endpoint for exchange (8). Last, although the follow-up protocol was not predetermined due to the retrospective nature of the study, the results can be generalized because it was a multicenter study and all of the participating institutions were hub medical institutions that provide cancer treatment for their respective prefectures in Japan. Conclusion Sixteen percent of BCRs occurred at 5 years after RP. Although the preoperative PSA levels of the patients were relatively low, there was one case that advanced to metastasis. Because a positive surgical margin was the predictor of BCR at <5 and 5 years after RP, cases that involve a positive surgical margin should be followed up for a long period of time. Conflict of interest statement None declared. References 1. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer JAMA Oncol 2015;1: Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. ARNHEM: European Association of Urology, Rosenfeld S. NCCN clinical practice guidelines in oncology (NCCN Guidelines ) prostate cancer. Washington: National Comprehensive Cancer Network, Reiner WG, Walsh PC. An anatomical approach to the surgical management of the dorsal vein and Santorini s plexus during radical retropubic surgery. J Urol 1979;121: Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59: Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170: Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, Walsh PC. Can we stop prostate specific antigen testing 10 years after radical prostatectomy? J Urol 2011;186: Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 2014;281: Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Longterm hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164: Caire AA, Sun L, Ode O, et al. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology 2009;74: Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25: MacDonald OK, Schild SE, Vora S, et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology 2004;64: Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299: Ahove DA, Hoffman K E, Hu JC, Choueiri TK, D Amico AV, Nguyen PL. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence? Implications for a riskadapted follow-up strategy. Urology 2010;76: Graefen M, Noldus J, Pichlmeier U, et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 1999;36: Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediateterm results. J Urol 1998;160: Murai M. Japanese Classification of Prostate Cancer. 3rd edn. Tolyo: The Japanese Urological Association, Ploussard G, Agamy MA, Alenda O, et al. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. BJU int 2011;107: Rouanne M, Rode J, Campeggi A, et al. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years of follow-up. Scandinavian. J Urol 2014;48: Yokomizo A, Murai M, Baba S, et al. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pt and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multiinstitutional outcome study in Japan. BJU int 2006;98: Yossepowitch O, Briganti A, Eastham JA, et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 2014;65: Loeb S, Sutherland DE, D Amico AV, Roehl KA, Catalona WJ. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology 2008;72:
NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationInterval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer
DOI 10.1007/s00345-013-1125-0 ORIGINAL ARTICLE Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer D. M. Bolton A. Ta M. Bagnato
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationOncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting
END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:
More informationDepartment of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(1) 74 79 doi: 10.1093/jjco/hyw150 Advance Access Publication Date: 12 October 2016 Original Article Original Article
More informationA Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy
1254 A Nomogram Predicting Long-term Biochemical Recurrence After Radical Prostatectomy Nazareno Suardi, MD 1,2 Christopher R. Porter, MD 3 Alwyn M. Reuther, MD 4 Jochen Walz, MD 1,5 Koichi Kodama, MD
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationRADICAL PROSTATECTOMY IS ONE
ORIGINAL CONTRIBUTION Risk of Prostate Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy Stephen J. Freedland, MD Elizabeth B. Humphreys, BS Leslie A. Mangold, MS Mario
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationOncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationEvaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion
Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationClinical Study Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer
ISRN Oncology Volume 2013, Article ID 239241, 7 pages http://dx.doi.org/10.1155/2013/239241 Clinical Study Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationincision into an otherwise organ-confined cancer [1,5].
28 The Authors. Journal compilation 28 BJU International Original Article IMPACT ON PROGRESSION OF POSITIVE SURGICAL MARGINS AFTER RP PFITZENMAIER et al. BJUI BJU INTERNATIONAL Positive surgical margins
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationDepartment of Urology, Washington DC Veterans Affairs Medical Center, Washington, DC, USA 4
Original Article Prostate Int 2013;1(1):31-36 P R O S T A T E INTERNATIONAL Robotic-assisted prostatectomy and open radical retropubic prostatectomy for locally-advanced prostate cancer: multi-institution
More informationGood Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic Prostatectomy
european urology 54 (2008) 344 352 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Good Outcome for Patients with Few Lymph Node Metastases After Radical Retropubic
More informationNEARLY MEN (27% OF
RELIMINARY COMMUNICATION rostate Cancer Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical rostatectomy Bruce J. Trock, hd Misop Han, MD Stephen
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More informationOncological outcomes after robot-assisted radical prostatectomy: long-term follow-up in 4803 patients
Oncological outcomes after robot-assisted radical prostatectomy: long-term follow-up in 4803 patients Shyam Sukumar, Craig G. Rogers, Quoc Dien Trinh, Jesse Sammon, Akshay Sood, Hans Stricker, James O.
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationRADICAL PROSTATECTOMY IS SElected
ORIGINAL CONTRIBUTION Adjuvant for Pathologically Advanced Prostate Cancer A Randomized Clinical Trial Ian M. Thompson, Jr, MD Catherine M. Tangen, DrPH Jorge Paradelo, MD M. Scott Lucia, MD Gary Miller,
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationACR Appropriateness Criteria Postradical Prostatectomy Irradiation in Prostate Cancer EVIDENCE TABLE
1. Bottke D, de Reijke TM, Bartkowiak D, Wiegel T. Salvage radiotherapy in with persisting/rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer. 009;45 Suppl 1:148-157.. Valicenti RK,
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationCorey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2*
Foster et al. Radiation Oncology 2014, 9:245 RESEARCH Open Access Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical
More informationResearch Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer
Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy
More informationDong Hoon Lee, Kyo Chul Koo, Seung Hwan Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong and Byung Ha Chung
Jpn J Clin Oncol 2013;43(5)553 558 doi:10.1093/jjco/hyt041 Advance Access Publication 11 April 2013 Low-risk Prostate Cancer Patients Without Visible Tumor (T1c) On Multiparametric MRI Could Qualify for
More informationOutcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing Radical Prostatectomy
european urology 52 (2007) 1058 1066 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Prostate Cancer Patients with Initial PSA I 20 ng/ml Undergoing
More informationReview Article Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions
Prostate Cancer Volume 2012, Article ID 963417, 8 pages doi:10.1155/2012/963417 Review Article Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions Pirus Ghadjar, 1 Daniel
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationUltra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pt2-4n0m0 prostate cancer
Taguchi et al. BMC Urology 2014, 14:81 RESEARCH ARTICLE Open Access Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pt2-4n0m0 prostate cancer
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationmid-term follow-up of 1115 procedures
1 2 3 Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: mid-term follow-up of 1115 procedures 4 5 6 7 8 9 Alexandre Paul*, Guillaume Ploussard*, Nathalie Nicolaiew, Evanguelos
More informationThe prognostic significance of percentage of tumour involvement according to disease risk group in men treated with radical prostatectomy
(2011) 13, 828 832 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE The prognostic significance of percentage of tumour involvement according to disease
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment
ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH
More informationSalvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration
EUROPEAN UROLOGY 60 (2011) 205 210 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Markus Graefen on pp. 211 213 of this issue
More informationBJUI. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis
BJUI BJU INTERNATIONAL Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis Ruslan Korets, Catherine M. Seager, Max S. Pitman, Gregory W. Hruby, Mitchell C. Benson and
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationProstate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomy
1 di 10 26/12/2015 17.15 Urol Ann. 2015 Oct-Dec; 7(4): 433 437. doi: 10.4103/0974-7796.152118 PMCID: PMC4660691 Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationValidation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System
Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationRobotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes
UROLCHI World J Urol DOI 10.1007/s00345-015-1515-6 ORIGINAL ARTICLE Robotic assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes Rodrigo A.
More informationCAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy
Original research CAPRA-S predicts outcome for adjuvant and salvage external beam radiotherapy after radical prostatectomy Michel Zimmermann, MD; 1 Guila Delouya, MD, MSc; 1,2 Abdullah M. Alenizi, MD;
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 472 487 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Judd W. Moul on pp. 488 490 of this issue
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More information